Qiagen, 834507, HSMD Online, For-prof/Clin Use, 10 Users

Annual subscription to QIAGEN’s Human Somatic Mutation Database (HSMD), a web-based application that allows you to harness genetic insights from QIAGEN’s real-world oncology dataset combined with knowledge from two decades of expert curation. Access to an online user interface for 10 users.
Show more

Features

- Over 1.3 million mutations
- Over 300,000 clinical oncology cases
- Over 3.4 million relationships from PubMed, drug labels, clinical trials, clinical guidelines and public databases
- Over 70,000 new oncology cases and 60,000 unique variants annually
- Covering over 1,000 cancer types

Product Details

Search, explore and synthesize weekly updated key findings about genes, diseases, variants, clinical trials and drugs from a single integrated database.

Performance

The Human Somatic Mutation Database (HSMD) is a web-based application that allows you to harness genetic insights from QIAGEN’s real-world oncology dataset combined with knowledge from 2 decades of expert curation. HSMD contains over 300,000 clinical oncology cases and over 1.3 million mutations associated with over 3.4 million relationships from PubMed, drug labels, clinical trials, clinical guidelines and public databases such as HGMD or gnomAD. The comprehensive, weekly updated aggregation of structured content delivers valuable scientific information that enables scientists to search and explore biological, clinical, and disease-relevant mutations and genes. HSMD covers content for spontaneous mutations as well as cancer-associated inherited variants, to give full insights into the complexity of cancer genetics, and the oncogenic potential of a mutation.

Principle

HSMD data has been curated, collected and standardized through manual curation by scientific experts, ensuring quality, accuracy.

Procedure

HSMD is easily accessed online from your computer. The search interface allows you to interrogate our knowledgebase. The content is updated weekly and software is typically updated quarterly.

Applications

Spot key findings from tumor molecular profile, reduce the operational bottleneck by interrogating just one database, accelerate cancer research and drug development programs.